-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.O1.6 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Charting The Future Of MPN Therapies

Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
adult, Research, clinical trials, MPN, Combination therapy, Clinical Research, Chronic Myeloid Malignancies, Diseases, patient-reported outcomes, Therapies, Adverse Events, Myeloid Malignancies, Study Population, Human
Sunday, December 10, 2023: 4:30 PM-6:00 PM
Ballroom 20CD (San Diego Convention Center)
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center and Shireen Sirhan, MD, FRCP, Jewish General Hospital
Bose: Incyte, BMS, CTI, Morphosys, Blueprint, Cogent, Sumitomo, Ionis: Honoraria, Research Funding; Kartos, Telios, Disc, Janssen, Geron: Research Funding; GSK, Novartis, Karyopharm, AbbVie, Pharma Essentia, Jubilant, Morphic: Honoraria. Sirhan: Novartis: Honoraria, Research Funding; GSK: Honoraria.
Session: In this session, we turn our attention to ruxolitinib and its synergistic potential in the treatment of myeloproliferative neoplasms (MPN). The primary focus will be on the use of ruxolitinib in polycythemia vera and emerging combinations of ruxolitinib with other therapeutic agents in myelofibrosis. By highlighting the latest research abstracts, this session is poised to stimulate rich discussions on the advantages, challenges, and nuances of these combination therapies. Whether you're deeply embedded in hematology research or are venturing into the MPN arena, this session promises a deep dive into the innovative realm of ruxolitinib combinations, hinting at the next frontier in MPN management.
4:30 PM

Steffen Koschmieder1,2,3, Susanne Isfort1,2,3*, Lino L. Teichmann4,5*, Philippe Schafhausen6*, Florian Heidel7,8, Andreas Hochhaus, MD9, Martin Griesshammer10,11, Katja Sockel, MD12*, Philipp Jost13,14*, Denise Wolleschak15*, Konstanze Döhner16, Joachim R. Goethert, MD17, Markus P. Radsak18*, Marinela Augustin19*, Heiko Becker, MD20*, Aristoteles Giagounidis21, Markus Schaich22*, Martine Klausmann23*, Nikolas Von Bubnoff24*, Frank Stegelmann16*, Maike Kortmann3,25*, Julia Frank26,27*, Martin Hellmich26,27* and Tim H. Brümmendorf1,3

1Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, NRW, Germany
2Shared first authorship, Aachen, Germany
3Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
4Department of Medicine III, University Hospital Bonn, Bonn, Germany
5Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Bonn, Germany
6University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7Internal Medicine C, University Medicine Greifswald, Greifswald, Germany
8Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany
9Universitätsklinikum Jena, Jena, Germany
10University of Bochum, Bochum, Germany
11University Clinic for Hematology, Oncology, Hemostasis and Palliative Care, Johannes Wesling Medical Center, University of Bochum, Minden, Germany
12Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany
13Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria
14Medical Department III, Hematology and Oncology, and Center for Translational Cancer Research, Translatum, Technical University of Munich, Munich, DEU
15Department of Hematology/Oncology, Otto-von-Guericke University Medical Center Magdeburg, Magdeburg, DEU
16Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
17Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany
18Department of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
19Klinikum Nürnberg Nord, Schwerpunkt Onkologie/Hämatologie, Klinik für Innere Medizin 5, Universitätsklinik Der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany
20Department of Hematology, Oncology and Stem Cell Transplantation, Universitätsklinikum Freiburg, Freiburg, Germany
21Dept. Oncology, Hematology and Palliative Care, Marienhospital Düsseldorf, Düsseldorf, Germany
22Department of Hematology, Oncology and Palliative Medicine, Rems-Murr Klinikum, Winnenden, Germany
23Gemeinschaftspraxis Aschaffenburg, Aschaffenburg, Germany
24Department of Hematology and Oncology, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
25Center for Translational & Clinical Research (CTC-A), Faculty of Medicine, RWTH Aachen University, Aachen, Germany
26Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
27Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Cologne, Germany

4:45 PM

Naveen Pemmaraju, MD1, Adam J Mead, MRCP, FRCPath, PhD2,3, Tim CP Somervaille, PhD FRCP FRCPath4, James K McCloskey, MD5, Francesca Palandri, MD6*, Steffen Koschmieder7,8, David Lavie9*, Brian Leber, MD10, Su-Peng Yeh, MD11*, Maria Teresa Gómez-Casares, MD, PhD12*, Emanuele Ammatuna, MD, PhD13*, Ho-Jin Shin, MD14*, Keita Kirito, MD15, Eric Jourdan, MD, PhD16*, Timothy Devos, MD17,18*, Hun S Chuah19*, Atanas Radinoff20*, Andrija Bogdanovic, Professor21,22*, Rastislav Moskal, PharmD23*, Qi Jiang23*, Avijeet S Chopra23*, Elektra Papadopoulos23*, Jalaja Potluri24 and Francesco Passamonti, MD25*

1Department of Leukemia, MD Anderson Cancer Center, Houston, TX
2Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR, Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
3Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
4Cancer Research UK Manchester Institute, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom
5Department of Leukemia, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ
6Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
7Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany
8Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany
9Hadassah Medical Center, Jerusalem, Israel
10Division of Hematology, Juravinski Cancer Center, Hamilton, ON, Canada
11Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
12Hospital Universitario de Gran Canaria Dr. Negrín. Universidad de Las Palmas de Gran Canaria., Las Palmas de Gran Canaria, Spain
13Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
14Department of Hematology-Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of (South)
15Department of Hematology and Oncology, University of Yamanashi, Chuo, Japan
16Hematologie Clinique, CHU de Nimes, Nimes, France
17Department of Hematology, University Hospitals Leuven, Leuven, Belgium
18Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium
19Department of Haematology, Royal Perth Hospital, Perth, Australia
20Clinic of Haematology, St.Ivan Rilski University Multidisciplinary Hospital, ., Bulgaria
21Faculty of Medicine, University of Belgrade, Belgrade, Serbia
22Clinic of Hematology, University Clinical Center Serbia, Belgrade, Serbia
23AbbVie Inc., North Chicago, IL
24AbbVie Inc, North Chicago, IL
25Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano, Policlinico di Milano, Ospedale Maggiore, Fondazione I.R.C.C.S. Ca Granda, Milano, Italy

5:00 PM

Harinder Gill, MD, MBBS, FRCP, FRCPath1, Lester Au1*, Garret Man Kit Leung1*, Dorothy Tsai1*, Rita Yim, PhD1*, Lynn Chin1*, Vivian Li1*, Paul Lee1*, Rock Yuk Yan Leung2*, Elaine Lee, MD3*, Hugh Young Rienhoff Jr., MD4 and Yok Lam Kwong, MD1*

1Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
2Department of Pathology, The University of Hong Kong, Hong Kong, Hong Kong
3Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, Hong Kong
4Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ

5:15 PM

Srinivas K. Tantravahi, MBBS1, Ashwin Kishtagari, MBBS2, Keri Maher, DO3, Sanjay Mohan, MD, MSCI4, Josef T. Prchal, MD5, Xulong Wang6*, Kamal Chamoun6*, Christopher J Walker, PhD6*, Pietro Taverna, PhD7 and Haris Ali, MD8

1Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake Cty, UT
2Division of Hematology & Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Franklin, TN
3Massey Cancer Center, Virginia Commonwealth University, Richmond, VA
4Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
5Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
6Karyopharm Therapeutics, Newton, MA
7Karyopharm Therapeutics Inc., Newton, MA
8Department of Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA

5:30 PM

David Lavie1*, Vincent Ribrag, MD2, Michael Loschi, MD, PhD3*, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, PhD4*, Maan Alwan5*, Adi Schacham Abulafia6*, Jesús María Hernández-Rivas, PhD7, Yulia Volchek8*, Chun Yew Fong9*, Massimiliano Bonifacio, MD10*, Jean-Jacques Kiladjian, MD, PhD11, Jean-Christophe Ianotto, MD, PhD12*, Valentín García Gutiérrez, PhD13, Alessandra Tucci, MD14, Blanca Xicoy, MD15*, Haifa Kathrin Al-Ali, MD/Prof16*, Moshe Talpaz, MD17, Jonathan M. Gerber, MD18, Indu Raman4*, Ciprian Tomuleasa19*, Si Tuen Lee-Hoeflich20*, Sharmila Das21*, Bin Wu20*, Qian Zhao22*, Eunhee Kim23*, Oriana Esposito24*, Yu Liu20*, Zariana Nikolova24*, Christopher Tehlirian20*, Shodeinde Coker22* and Rosa Ayala, MD25*

1Hadassah Medical Center, Jerusalem, Israel
2Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy Institute of Cancer,, Villejuif, France
3Centre Hospitalier Universitaire de Nice, Nice, France
4Epworth HealthCare, Melbourne, VIC, Australia
5Perth Blood Institute, West Perth, Western Australia, Australia
6Davidoff Cancer Center, Institute of Hematology, Petach Tikva, Israel
7Department of Medicine, Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain
8Department of Hematology, Assaf Harofeh Medical Center, Tzrifin, Israel
9Department of Hematology, Austin Health, Heidelberg, VIC, Australia
10Department of Medicine, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
11Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, INSERM, Centre d'Investigations Cliniques (CIC 1427), Paris, France
12Centre Hospitalier Universitaire de Brest,, Brest, France
13Hospital Universitario Ramon y Cajal, Alcala University, Translational Hematology Group, IRYCIS, Madrid, Spain
14Hematology, ASST Spedali Civili, Brescia, Italy
15Hematology Service, Hospital Germans Trias I Pujol, Institut Català Oncologia, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
16Krukenberg Cancer Center Halle, University Medicine Halle, Halle, Germany
17Division of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI
18UMass Chan Medical School, Worcester, MA
19Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
20Bristol Myers Squibb, Cambridge, MA
21Bristol Myers Squibb, Princeton, NJ
22Bristol Myers Squibb, Lawrenceville, NJ
23Bristol Myers Squibb, Berkeley Heights, NJ
24Centre for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain
25Hospital Universitario 12 de Octubre, Madrid, Spain

5:45 PM

Sanjay Mohan, MD, MSCI1, Stephen Oh, MD, PhD2*, Jean-Jacques Kiladjian, MD, PhD3, Masahiro Takeuchi, MD, PhD4*, Jason Gotlib, MD5*, Ellen K. Ritchie, MD6, Taizo Shimomura, MD, PhD7*, Paola Guglielmelli, MD, PhD8, Anthony M. Hunter, MD9*, Francesca Palandri, MD10*, Francoise Boyer, MD11*, Alessandro Rambaldi, M.D.12, Takehiko Mori, MD, PhD13*, Tomoki Ito, MD, PhD14, Betty Lamothe, PhD15*, Yan-Ou Yang, PhD15*, Yi Cui, PhD15*, Francis Seguy, MSc16*, Amanda McBride, MD, PhD15* and Prithviraj Bose, MD17

1Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
2Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
3Hopital Saint-Louis, Paris, France
4Chiba Cancer Center, Chiba, JPN
5Division of Hematology, Stanford Cancer Institute/ Stanford University School of Medicine, Stanford, CA
6Weill Cornell Medical College, Cornell University, New York, NY
7Kumamoto Shinto General Hospital, Kumamoto, KUM, JPN
8Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
9Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta
10IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy, Bologna, Italy
11Centre Hospitalier Universitaire Angers, Angers, France
12Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo BG, Italy
13Department of Hematology, Tokyo Medical and Dental University School of Medicine, Bunkyo-Ku, JPN
14Kansai Medical University Hospital, Hirakata, JPN
15Incyte Corporation, Wilmington, DE
16Incyte Biosciences International Sàrl, Morges, Switzerland
17The University of Texas MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH